Physician profile
Indira R Devu
NPI 1871530139
$3,085.98
in general payments reported to CMS, 2019-2025
19 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $476 · 2021: $920 · 2022: $439 · 2023: $262 · 2024: $276 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $877.71 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $761.77 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $277.45 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $197.08 | 2019-2021 | |
| Lilly USA, LLC | $124.01 | 2020-2025 | Mounjaro, Jardiance |
| Abbvie INC. | $122.92 | 2021-2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $122.30 | 2022-2025 | Rexulti, Jynarque |
| Exact Sciences Corporation | $113.57 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $89.79 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $87.35 | 2022 | |
| Amarin Pharma, INC. | $80.05 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.29 | 2022-2024 | |
| Dexcom, INC. | $51.84 | 2021-2024 | Dexcom G6 Transmitter |
| Omeza LLC | $31.11 | 2023 | |
| Allergan, INC. | $24.01 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linus Health, INC. | $23.60 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.90 | 2019 | |
| Horizon Therapeutics Plc | $14.23 | 2023 | Krystexxa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Devu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.